FDA

Showing 15 posts of 1404 posts found.

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024
Medical Communications FDA, Oncology, Roche, lung cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …

GSK’s meningococcal vaccine candidate accepted for FDA review

April 16, 2024
Medical Communications FDA, GSK, Immunology, meningococcal

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) …

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

April 15, 2024
Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

April 10, 2024
Research and Development FDA, Oncology, Oryzon, lung cancer

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …

FDA accepts UCB’s sBLA for Bimzelx

April 5, 2024
Medical Communications Bimzelx, FDA, Pharmacy, UCB, sBLA

UCB has announced that the US Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application …

FDA approves Basilea’s antibiotic Zevtera for three indications

April 4, 2024
Medical Communications Basilea Pharmaceutica, FDA, Infections and infestations, Zevtera, antibiotic

Basilea Pharmaceutica has announced that the US Food and Drug Administration (FDA) has approved Zevtera (ceftobiprole medocaril sodium for injection), …

FDA approves Eko Health’s AI for heart failure detection

April 3, 2024
Medical Communications Cardiology, Eko Health, FDA, heart failure, low ejection fraction

Eko Health has announced that the US Food and Drug Administration (FDA) has approved its Low Ejection Fraction (Low EF) …

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

April 2, 2024
Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …

FDA approves Roche’s test for malaria in blood donors

April 2, 2024
Business Services FDA, Infections and infestations, blood donation, malaria

Roche has announced that the US Food and Drug Administration (FDA) has approved its cobas Malaria test for use on …

FDA approves Merck’s Winrevair for PAH treatment

March 27, 2024
Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

Heidelberg Pharma gains FDA ODD for ATAC candidate

March 27, 2024
Research and Development FDA, Oncology, heidelberg pharma, multiple myeloma

Heidelberg Pharma has announced that it has gained Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) …

FDA approves AstraZeneca’s Ultomiris for NMOSD treatment

March 25, 2024
Medical Communications AstraZeneca, FDA, Neurology, Ultomiris, neuromyelitis optica spectrum disorder

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) as the first and only …

FDA approves J&J’s Opsynvi for PAH treatment

March 25, 2024
Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …

FDA approves Idorsia’s Tryvio for treatment of high blood pressure

March 22, 2024
Medical Communications Cardiology, FDA, Tryvio, blood pressure, blood presure, hypertension

Idorsia has announced that the US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension …

Boehringer Ingelheim’s Spevigo gains additional approvals in US and China

March 20, 2024
Medical Communications Boehringer Ingelheim, Dermatology, FDA, Spevigo, psoriasis

Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and Drug Administration (FDA) for the …

Latest content